Interpace Biosciences, Inc. (IDXG)

Market Cap	11.66M
Revenue (ttm)	44.89M
Net Income (ttm)	4.70M
Shares Out	4.40M
EPS (ttm)	1.07
PE Ratio	2.39
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	1,150
Open	2.650
Previous Close	2.900
Day's Range	2.650 - 2.650
52-Week Range	0.820 - 3.540
Beta	0.67
Analysts	n/a
Price Target	n/a
Earnings Date	Mar 7, 2025

About Interpace Biosciences

Interpace Biosciences, Inc. provides molecular diagnostic tests, bioinformatics, and pathology services for evaluating cancer risk in the United States. The company offers PancraGEN, a pancreatic cyst and pancreaticobiliary solid lesion genomic test for the diagnosis and prognosis of pancreatic cancer; PanDNA, a molecular only version of PancraGEN; and ThyGeNEXT, an oncogenic mutation panel to identify malignant thyroid nodules. It also provides ThyraMIR assesses thyroid nodules for risk of malignancy utilizing a proprietary microRNA gene-expre...

• Industry: Diagnostics & Research
• Sector: Healthcare
• Founded: 1986
• Employees: 108
• Stock Exchange: OTCMKTS
• Ticker Symbol: IDXG